Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Claritin-D “Staying Tough” Behind The Counter With Pseudoephedrine

This article was originally published in The Tan Sheet

Executive Summary

New ads for Schering-Plough's Claritin-D aim to position the manufacturer as taking a stand by declining to join the ranks of OTC manufacturers who are reformulating their pseudoephedrine-containing products with phenylephrine
Advertisement

Related Content

Phenylephrine “Not Significantly Different From” Placebo – Schering Study
Phenylephrine “Not Significantly Different From” Placebo – Schering Study
Phenylephrine “Not Significantly Different From” Placebo – Schering Study
Sales & Earnings In Brief
Meth Strategy Includes Tracking Success Of National Versus State Policies
Meth Strategy Includes Tracking Success Of National Versus State Policies

Topics

Advertisement
UsernamePublicRestriction

Register

PS099797

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel